Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
Completed
Millennium Pharmaceuticals, Inc.
Phase 1
2009-10-01
The primary objective of this study is to determine the safety profile, tolerability, and
maximum tolerated dose of ixazomib citrate (MLN9708) when taken orally on a weekly dosing
schedule by patients with relapsed and refractory multiple myeloma (RRMM). Secondary
objectives include pharmacokinetics and response rates.
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Recruiting
National Cancer Institute (NCI)
Phase 2
2012-01-31
This phase II trial studies how well ixazomib citrate works in treating patients with
multiple myeloma that has returned after a period of improvement (relapsed) but is not
resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth.
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Recruiting
Mayo Clinic
Phase 2
2012-01-31
This phase II trial studies how well ixazomib citrate works in treating patients with
multiple myeloma that has returned after a period of improvement (relapsed) but is not
resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth.
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Active, not recruiting
Millennium Pharmaceuticals, Inc.
Phase 2
2012-12-03
This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell
transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Biological therapies, such as lenalidomide, may stimulate the immune system in different ways
and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be
effective in treating multiple myeloma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
